Compare KFRC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | EBS |
|---|---|---|
| Founded | 1962 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.6M | 529.9M |
| IPO Year | 1995 | 2006 |
| Metric | KFRC | EBS |
|---|---|---|
| Price | $29.58 | $12.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $34.75 | $15.00 |
| AVG Volume (30 Days) | 251.8K | ★ 867.1K |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.26 | 1.35 |
| Revenue | ★ $1,340,771,000.00 | $788,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | $13.31 | ★ $8.92 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.49 | $4.02 |
| 52 Week High | $61.81 | $13.41 |
| Indicator | KFRC | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 65.31 |
| Support Level | $29.00 | $10.63 |
| Resistance Level | $30.42 | $11.31 |
| Average True Range (ATR) | 1.06 | 0.59 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 71.58 | 96.47 |
Kforce Inc is a solutions firm specializing in technology, finance and accounting, and other professional staffing services. The company operates two business segments: 1) In technology segment it provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. 2) In FA segment company offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting business and cost analysis; and taxation and treasury. The majority of revenue is earned through the technology segment.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.